Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Nightstar Therapeutics Limited (NASDAQ: NITE) today and set a price target of $40. The company’s shares closed on Friday at $25.50.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 26.8% and a 53.0% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Nightstar Therapeutics Limited has an analyst consensus of Strong Buy, with a price target consensus of $32.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29.55 and a one-year low of $10.01. Currently, Nightstar Therapeutics Limited has an average volume of 125.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.
